The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

Date publication

janvier 2015

Journal

JACC. Heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25458174

Résumé

This study investigated whether galectin (Gal)-3 inhibition could block aldosterone-induced cardiac and renal fibrosis and improve cardiorenal dysfunction.

Mots clés

Acute Kidney Injury, chemically induced, Aldosterone, toxicity, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Galectin 3, antagonists & inhibitors, Heart Failure, chemically induced, Immunohistochemistry, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mineralocorticoid Receptor Antagonists, therapeutic use, Rats, Rats, Wistar, Spironolactone, therapeutic use

Référence

JACC Heart Fail. 2015 Jan;3(1):59-67